NEW YORK (Reuters) - Valeant Pharmaceuticals International Inc. agreed to acquire Salix Pharmaceuticals Ltd. for $158.00 per share, or a total enterprise value of $14.5 billion, the two companies said on Sunday.
The transaction, an all-cash tender offer for all the outstanding shares of Salix, was approved by the boards of directors of both companies, the companies said in a news release.
The merger is expected to yield more than $500 million in annual cost savings from the cost base of the combined company, the release said.
(Reporting by Herbert Lash; Editing by Frances Kerry)
Relacionados
- La CE dice que hay que centrarse en Minsk y no en opción de despliegue misión
- La CE aportará 13,7 millones de euros a Italia ante la creciente presión migratoria
- Grecia acepta la supervisión de la CE, el BCE y el FMI mientras reciba asistencia financiera
- Grecia retrasa la solicitud al Eurogrupo entre advertencias de la CE y Berlín
- La CE quiere que las pymes europeas dependan menos de los créditos bancarios
